PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

Summary

This research study aims to learn about how the body responds to food through different genetic pathways and how these responses may change during a short course of orforglipron. Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist that was approved by the U.S. Food and Drug Administration (FDA) on April 1, 2026, for long-term weight management. In longer studies, it has helped people lose weight and improve blood sugar, blood pressure, and cholesterol. By taking part, participants will receive detailed metabolic testing and may receive study results with additional information about their blood sugar and metabolic health.

Timeline

Start

2026-10-01

Primary completion

2029-09-30

Completion

2030-09-30

Drugs

Indications